Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer

Experimental Oncology

Volumn 29, Issue 3, 2007, Pages 192-196

  Yu, Zhigang ^a   Yang, Qifeng ^b,c   Sun, J ^b   Zhen, J ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Chemosensitivity; Dihydropyrimidine dehydrogenase; Fluorouracil

Indexed keywords

CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL;

EID: 36749002737     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
2. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330: 217.
3. Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006; 12: 159-64.
4. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 2004; 22: 2303-12.
5. nd. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002; 236: 295-302; discussion 302-3.
6. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939-50.
7. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51.
8. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405-12.
9. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986; 6: 781-4.
10. Queener SF, Morris HP, Weber G. Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas. Cancer Res 1971; 31: 1004-9.
11. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, Milano G. A role for dihydropyrimidine dehydrogenase andthymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 1517-22.
12. Schert U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 236-44.
13. Takebe N, Zhao SC, Ural AU, Johnson MR, Banerjee D, Diasio RB, Bertino JR. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther 2001; 8: 966-73.
14. Horiguchi J, Takei H, Koibuchi Y, Iijima K, Ninomiya J, Uchida K, Ochiai R, Yoshida M, Yokoe T, Iino Y, Morishita Y. Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 2002; 86: 222-5.
15. Li H, Suo Z, Zhang Y, Risberg B, Karlsson MG, Villman K, Nesland JM. The prognostic significance of thymidine Phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas. Histol Histopathol 2004; 19: 129-36.
16. Valenzuela AI, Redondo MJ, Pico Y, Font G. Determination of abamectin in citrus fruits by liquid chromatography - electrospray ionization mass spectrometry. J Chromatogr A 2000; 871: 57-65.
17. Yang QF, Sakurai T, Yoshimura G, Shan L, Suzuma T, Tamaki T, Umemura T, Kokawa Y, Nakamura Y, Nakamura M, Tang W, Utsunomiya H, Mori I, Kakudo K. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 2000; 61: 211-6.
18. Yu Z, Sun J, Zhen J, Zhang Q, Yang Q. Thymidylate synthase predicts for clinical outcome in invasive breast cancer. Histol Histopathol 2005; 20: 871-8.
19. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M. High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 1992; 51: 489-98.
20. Kakimoto M, Uetake H, Osanai T, Shirota Y, Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV, Sugihara K. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 2005; 223: 103-11.
21. Chorna IV, DatsyukLO, Stoika RS. Expression of Bax, Bad and Bcl-2 proteins under x-radiation effect towards human breast carcinoma MCF-7 cells and their doxorubicin-resistant derivatives. Exp Oncol 2005; 27: 196-201.
22. Furukawa T, Kubota T, Tanino H, Oura S, Yuasa S, Murate H, Morita K, Kozakai K, Yano T, Hoffman RM. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 2000; 20: 3657-8.
23. Tanino H, Oura S, Hoffman RM, Kubota T, Furukawa T, Arimoto J, Yoshimasu T, Hirai I, Bessho T, Suzuma T, Sakurai T, Naito Y. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 2001; 21: 4083-6.
24. Ariyoshi Y, Shimahara M, Tanigawa N. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 2003; 39: 701-7.
25. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002; 24: 437-42.
26. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T, Maekawa Y. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 2002; 7: 335-42.
27. Hirano Y, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Clinical usefulness of chemotherapy based on an in vitro chemosensitivity test in urothelial cancer patients. Anticancer Res 2001; 21: 4061-6.
28. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR, Hoffman RM. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 2000; 20: 2049-54.
29. Ooyama A, Takechi T, Toda E, Nagase H, Okayama Y, Kitazato K, Sugimoto Y, Oka T, Fukushima M. Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci 2006; 97: 510-22.
30. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-5.
31. Suto A, Kubota T, Fukushima M, Ikeda T, Takeshita T, Ohmiya H, Kitajima M. Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice. Oncol Rep 2006; 15: 1517-22.